News & Publications Careers Contact Us ABOUT NABRIVA PIPELINE & RESEARCH FOR INVESTORS CONTACT US Home / Contact Us Medical Information For Product information or to report an adverse event, product quality complaint, or exposure to XENLETA during pregnancy: 1-855-5NABRIVA, Press 1 (MON-FRI:9AM-5PM EST) Medical.Information@Nabriva.com Suspected adverse events may be reported to the FDA directly 1-800-FDA-1088 or www.fda.gov/medwatch Nabriva Therapeutics US, Inc. 414 Commerce Drive, Suite 120 Fort Washington, PA 19034 USA View Google map T +1 (610) 816-6640 F +1 (610) 816-6639 officeUS@nabriva.com Nabriva Therapeutics GmbH Leberstrasse 20 1110 Vienna Austria View Google map T +43 (0)1 740 93-0 F +43 (0)1 740 93-1900 office@nabriva.com FN 269261 Y VAT No.: ATU62319422 Nabriva Therapeutics plc 25-28 North Wall Quay, IFSC, Dublin 1, Ireland T +353 1 649 2000 officeIE@nabriva.com Nabriva Therapeutics Ireland DAC Alexandra House, Office 225/227 The Sweepstakes Ballsbridge Dublin 4 D04 C7H2 Republic of Ireland View Google map T +353 (0) 1 664 1700 officeIE@nabriva.com VAT No. 3514827BH Reg. No. 612454 Press Contact PR@nabriva.com Business Development Contact BD@nabriva.com Nabriva Response to COVID-19 Thank you to all the healthcare professionals for your tireless service on the frontlines of this pandemic. Due to COVID-19, the FDA has reported shortages of key drugs, including select antibiotics. Xenleta® (lefamulin) may be an alternative regimen for patients in need. Nabriva wants to reassure you that we have sufficient inventory of XENLETA IV and Oral tablets, available through designated specialty pharmacies or specialty distributors. Learn more at www.XENLETA.com. Again, to all the medical professionals, please be safe, take care of yourself and stay well. Best, Ted Schroeder CEO, Nabriva Therapeutics Continue to site Privacy Notice Patents Imprint Disclaimer Contact Us Careers Sitemap © Nabriva Therapeutics plc, Ireland Registration No. 599588, 25-28 North Wall Quay, Dublin 1, Ireland